Related Experiment Video
Updated: Jul 4, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma
Hao Song1, Qing Song2, Xiangkun Zhao1
1The Second Medical College, Binzhou Medical University, Yantai, China; Department of Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, China; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai, China.
Objective:
The purpose of this study is to study the in-vitro effects of multitarget inhibitor anlotinib on hypopharyngeal cancer cell proliferation and cell migration, and the underlying mechanism, which will provide new drug choices for hypopharyngeal cancer treatment.
Methods:
The Hypopharyngeal cancer Fadu cells were treated with anlotinib at a concentration of 0, 5, and 10 μmoL/L, respectively. Cell counting kit-8 and the colony-forming assay were used to detect the inhibition of cell proliferation. Wound-healing assay and transwell assay were used to detect the migration and invasion ability of cells. Flow cytometry was used to detect the effects of anlotinib on cell cycle and apoptosis. RT-qPCR and Western blot were used to measure gene expression levels.
Results:
CCK-8 and colony-forming assay showed that anlotinib could significantly inhibit cell proliferative activity. Wound-healing assay and transwell assay showed that anlotinib could inhibit cell migration and scratch. These results showed that anlotinib has obvious antitumor activity. Flow cell cycle experiment showed that anlotinib could promote Fadu cell apoptosis and block the G2/M phase for inhibiting cell proliferation. In addition, anlotinib decreased the expression of HIF-1α.
Conclusions:
Anlotinib has an excellent suppressing effect on the proliferation, migration, and invasion of hypopharyngeal cancer Fadu cells in-vitro. Moreover, it can play an anti-tumor role through blocking cell cycle G2/M and promoting apoptosis, which may be related to the decrease of HIF-1a expression. Our study would provide a potential treatment method for patients with hypopharyngeal cancer.
Level Of Evidence:
Level 3.
Insights
Anlotinib effectively inhibits hypopharyngeal cancer cell growth and migration in vitro. This multitarget inhibitor promotes apoptosis and blocks cell cycle progression, offering a potential new treatment for hypopharyngeal cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Hypopharyngeal cancer presents a significant therapeutic challenge.
- Novel therapeutic strategies are urgently needed to improve patient outcomes.
Purpose of the Study:
- To investigate the in-vitro anti-cancer effects of anlotinib on hypopharyngeal cancer cells.
- To elucidate the underlying molecular mechanisms of anlotinib's action.
- To evaluate anlotinib as a potential therapeutic agent for hypopharyngeal cancer.
Main Methods:
- Hypopharyngeal cancer Fadu cells were treated with varying concentrations of anlotinib.
- Cell proliferation was assessed using CCK-8 and colony-forming assays.
- Cell migration and invasion were evaluated via wound-healing and Transwell assays.
- Cell cycle distribution and apoptosis were analyzed by flow cytometry.
- Gene expression changes were measured using RT-qPCR and Western blot.
Main Results:
- Anlotinib significantly inhibited Fadu cell proliferation and colony formation.
- Anlotinib demonstrated potent inhibition of cell migration and invasion.
- Flow cytometry revealed that anlotinib induced G2/M cell cycle arrest and promoted apoptosis.
- Anlotinib treatment led to a decrease in HIF-1α expression.
Conclusions:
- Anlotinib exhibits significant anti-proliferative, anti-migratory, and anti-invasive effects on hypopharyngeal cancer cells in-vitro.
- The anti-tumor activity of anlotinib is mediated by cell cycle arrest at G2/M phase and induction of apoptosis.
- Reduced HIF-1α expression may contribute to anlotinib's anti-cancer effects.
- Anlotinib represents a promising therapeutic candidate for hypopharyngeal cancer treatment.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
